Stereotactic ablative body radiotherapy combined with immunotherapy: Present status and future perspectives

N. H. Rekers*, E. G. C. Troost, C. M. L. Zegers, W. T. V. Germeraad, L. J. Dubois, P. Lambin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

56 Downloads (Pure)


Radiotherapy is along with surgery and chemotherapy one of the prime treatment modalities in cancer. It is applied in the primary, neoadjuvant as well as the adjuvant setting. Radiation techniques have rapidly evolved during the past decade enabling the delivery of high radiation doses, reducing side-effects in tumour-adjacent normal tissues. While increasing local tumour control, current and future efforts ought to deal with microscopic disease at a distance of the primary tumour, ultimately responsible for disease-progression. This review explores the possibility of bimodal treatment combining radiotherapy with immunotherapy.
Original languageEnglish
Pages (from-to)391-395
JournalCancer Radiotherapie
Issue number5-6
Publication statusPublished - Oct 2014


  • Stereotactic ablative body radiotherapy
  • Immunotherapy

Cite this